With these posters, Partners4Access showcases its commitment to advancing health economics and outcomes research (HEOR) in orphan drugs and ATMPs.
Representing Partners4Access at ISPOR 2024 are Samantha Morrison, Executive Director and Marco Crisci, Senior Analyst.
Marco is the author of a poster investigating the concept of durability (long-term duration of effect) and commented:
“At Partners4Access, we pride ourselves in our comprehensive and high-quality primary research insights. The concept of durability (long-term duration of effect) is central to the value proposition of single-dose gene therapies, and is a key component considered in payer assessments. However, clinical trial durations are typically shorter than the duration of expected benefit for gene therapies, which can span several decades or a lifetime. In the absence long-term clinical data, gene therapy manufacturers must reassure payers on durability by other means. Supportive evidence (other than RCT data) can be leveraged as part of a comprehensive evidence package to support the claim of gene therapy durability; but to what extent do European payers accept and value supportive evidence? Our research and poster aimed to answer this question, and uncover supportive evidence types likely to be impactful during payer assessments.”
Samantha Morrison is presenting a poster written by Partners4Access’ Digital Lead, Darren Callahan, about DMD treatment landscape, how it is evolving and the critical need for stakeholders to understand and assess these developments using a social listening. RarePULSE® (Partners4Access’ omnichannel service) utilizes advanced analytics to deliver precise, actionable insights into patient and stakeholder experiences, allowing our customers to make data-driven decisions that improve outcomes. By spotlighting the lived experiences and concerns of those affected by DMD, we aim to provide a holistic view of the treatment landscape.
Samantha is looking forward to presenting the poster and ready to experience ISPOR:
“I’m looking forward to giving a voice to rare diseases in JCA session and the discussion surrounding if there will be an impact of Medicare price negotiation on Europe.”
The third poster written is by Johann Sanseau, Senior Analyst.
Johann’s poster focuses on one-time gene therapies and their varying success convincing cost-effectiveness (CE)-focused markets of their long-term durability. Additionally, the poster investigates CE markets that have lacked a consistent approach to the assumptions made around durability within economic models. The poster aims to determine how durability is assumed for previously assessed gene therapies to allow manufacturers to understand what are the key types of evidence that will support long-term durability claims in CE markets.
About ISPOR 2024
The ISPOR Europe 2024 conference, themed “Generating Evidence Toward Health and Well-Being,” will be held 17 – 20 November in Barcelona, Spain. The conference program centers on the importance of scientific evidence in understanding and improving the health and well-being of people across the globe. Sessions will focus on the science, practice, and policies of healthcare value assessment and promote a broader view of health economics and outcomes research (HEOR) that considers the physical, mental, and social health aspects of innovation.
About Partners4Access
Partners4Access (P4A) is a global consultancy specializing in market access for orphan drugs, gene therapies, and other rare disease treatments. P4A’s expertise lies in navigating the unique challenges of launching and accessing innovative therapies, helping clients bring life-saving treatments to patients around the world. With a team of experienced professionals, P4A provides tailored solutions to optimize pricing, reimbursement, and market access strategies.
For more information, please visit our website at www.partners4access.com
Contact
Owen Bryant
Creative Director
[email protected]
